N※N

BioElectronics Corporation: BioElectronics Announces Canadian Retail Distribution Contracts

  //health-fitness.news-articles.net/content/2009/ .. nces-canadian-retail-distribution-contracts.html
  Published in Health and Fitness on Tuesday, January 20th 2009 at 7:02 GMT, Last Modified on 2009-01-20 07:03:27 by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

FREDERICK, MD--(Marketwire - January 20, 2009) - BioElectronics Corp. (PINKSHEETS: [ BIEL ]), the maker of ActiPatch® Therapy, the drug free anti-inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy that revolutionizes the way people heal, today announced that Katz Group, Canada's largest drugstore chain, will begin carrying the company's products at the end of this month in its Rexall, Guardian, PharmaPlus and IDA drug stores.

"This is significant news for BioElectronics. We were already seeing strong success with London drugs in Western Canada and we have recently completed a very successful test with Zeller's Pharmacies. The addition of these new chains, which give us almost Canada-wide coverage, should increase our sales levels further," commented Andrew Whelan, CEO of BioElectronics. "We are very encouraged by our international sales growth, not only within Canada, but also within the European Union."

BioElectronics' Canadian sales efforts, through its distributor [ Locin Industries ], Inc., are supported by a national print advertising campaign in leading Canadian magazines and an aggressive Web advertising program. Later this year these efforts will be enhanced with the addition of a Canadian television advertising campaign.

About BioElectronics Corporation

[ BioElectronics Corporation ] is the maker of the Allay™ Menstrual Pain Therapy, the RecoveryRx™ Therapy, the [ HealFast™ Therapy for veterinary applications ] and ActiPatch® Therapy. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for [ the relief of pain in musculoskeletal complaints ]. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.